BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma (Cancer Network) - Sep 29, 2026 - "...initial results from a first-in-human phase 1 trial (NCT06153251) presented at the 23rd Annual International Myeloma Society (IMS) Meeting & Exposition....At a median follow-up of 12 months among all 58 treated patients, the overall response rate (ORR) was 83%, and 74% of patients achieved a very good partial response (VGPR) or better. By dose level, the ORR was 67% at 25 × 10⁶ CAR T cells, 95% at 75 × 10⁶ cells, and 93% at 150 × 10⁶ cells, with a complete response (CR) or better rate of 67% at the second highest dose level and 79% at the highest dose level....Among the 16 BCMA- and GPRC5D-naive patients treated at the 75 × 10⁶ or 150 × 10⁶ dose levels, the ORR was 100%; all patients (100%) achieved a very good partial response (VGPR) or better, and the complete response rate was 88% (n = 14/16). All 16 of these patients were evaluable for measurable residual disease (MRD), and 100% were MRD negative at the 10⁻⁵ threshold per flow cytometry."
First-in-human • P1 data • Multiple Myeloma
|